Vaccine for All ‘Decent Amount’ of Weeks Away, Johns Hopkins' Sauer Says

The transcript discusses the progress and challenges in developing a COVID-19 vaccine, highlighting Moderna's advancements and the importance of phase three trials. It explores strategies for vaccine distribution, prioritizing vulnerable populations and healthcare workers. The discussion also addresses the challenges of achieving herd immunity due to public hesitancy and the need for effective communication. Finally, it examines the uncertainty around immunity duration and the potential for a seasonal vaccine.

What are the key challenges that vaccines, including those for coronavirus, face during the phase three trials?

How does the rollout of a vaccine differ in various countries, and what strategies are being considered?

What factors contribute to vaccine hesitancy among the population?

What are the implications of requiring two doses for a vaccine, and how might this affect public willingness to get vaccinated?

What is currently known about the duration of immunity following natural COVID-19 infection and vaccination?